KNOXVILLE, Tenn.--(BUSINESS WIRE)--ProNova Solutions, a leading manufacturer of next generation proton therapy equipment, announced today that the University of Oxford, in collaboration with Oxford University Hospitals NHS Trust, will partner with ProNova Solutions to incorporate ProNova’s SC360 proton therapy system in Oxford University’s Precision Cancer Medicine Institute (PCMI).
The PCMI will be a clinical research facility for the development, testing and implementation of personalized, minimally invasive cancer treatments combined with molecularly targeted agents for diagnosis, imaging and therapy. Proton Therapy will play a key role in the focused research directed to improving curative treatments for patients with early-stage cancer where minimizing side effects has substantial personal, societal and economic benefits.
Help employers find you! Check out all the jobs and post your resume.
